Cogent Biosciences (COGT) – Hot FDA News
-
Cogent Biosciences (COGT) Declines 40% Following Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with AdvSM
-
Cogent Biosciences (COGT) Climbs 33% Following Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial
Back to COGT Stock Lookup